期刊文献+

泛素-蛋白酶体抑制剂对血管平滑肌细胞凋亡和动脉粥样硬化的影响 被引量:2

Effects of ubiquitin-proteasome inhibitor on apoptosis of vascular smooth muscle cells and atherosclerosis
下载PDF
导出
摘要 泛素-蛋白酶体系统(Ubiquitin proteasome system,UPS)是真核细胞内蛋白质降解的核心途径,对细胞周期、炎症反应、细胞凋亡的调节起十分重要的作用。血管平滑肌细胞(Vascular smooth muscle cells,VSM C)作为血管壁的重要细胞成分,其增殖与凋亡的失平衡是决定动脉粥样硬化发生、发展的关键环节。在VSM C中,细胞凋亡与UPS活性密切相关,且UPS对动脉粥样硬化各个阶段有显著的调节作用。泛素-蛋白酶体抑制剂(Ubiquitin-proteasome inhibitors,UPI)通过抑制凋亡相关蛋白的降解,从而调控VSMC的凋亡,影响动脉粥样硬化形成的各个阶段。本文综述了UPI对VSMC凋亡的影响及其在动脉粥样硬化各阶段的调节作用。 Ubiquitin-proteasome system(UPS) is the principal degradation route of proteins in eukaryotic cells,thus playing a crucial role in the regulation of cell cycle inflammation and apoptosis.The imbalance between proliferation and apoptosis of vascular smooth muscle cells(VSMC),an important cellular component of the vessel wall,is a key in occurrence and development of atherosclerosis.VSMC apoptosis has been associated with UPS,and the UPS has a significant regulatory role in the various stages of atherosclerosis.Proteasome inhibitor(UPI) affects all stages of atherosclerosis formation by inhibiting the degradation of apoptosis-related proteins and regulating the apoptosis of VSMC.This paper reviews the effect of UPI on VSMC apoptosis and regulation of the various stages of atherosclerosis.
作者 王莹 孙瑞红
出处 《实用药物与临床》 CAS 2016年第6期768-772,共5页 Practical Pharmacy and Clinical Remedies
基金 2013年黑龙江省自然科学基金资助项目(H201-306)
关键词 泛素-蛋白酶体抑制剂 血管平滑肌细胞 凋亡 动脉粥样硬化 Ubiquitin-proteasome inhibitor Vascular smooth muscle cells Apoptosis Atherosclerosis
  • 相关文献

参考文献25

  • 1Schwartz AL, Ciechanover A. Targeting proteins for destruc- tion by the ubiquitin system: implications for human pathobiol-ogy[ J]. Annu Rev Pharmaco1,2009 ,49 :73-96.
  • 2Sahara K, Kogleck L, Yashiroda H, et al. The mechanism for molecular assembly of the proteasome [ J ]. Adv Biol Regul, 2014,54:51-58.
  • 3Marilene D, Laurindo FRM. Physiological and pathological role of the ubiquitin proteasome system in the vascular smooth muscle cell[ J]. Cardiovasc Res,2012,95(2) :183-193.
  • 4Chad A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma [ J ]. Biologics, 2010,4:273-287.
  • 5Teru H, Constantine M, Masaharu A, et al. Molecular mecha- nisms mediating antimyeloma activity of proteasome inhibitor PS-341 [ J ]. Blood,2003,101 ( 11 ) : 1530-1534.
  • 6Kim K. Proteasome inhibitors sensitize human vascular smooth muscle cells to Fas ( CD95 ) -mediated death [ J ]. Biochem Bioph Res Co,2001,281 ( 2 ) : 305 -310.
  • 7Nikrad M, Johnson T,Puthalalath H, et al. The proteasome in- hibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim [ J ]. Mol Cancer Ther,2005,4 ( 3 ) :443-449.
  • 8Minamino T, Komuro IM. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease [ J ]. Circ Res, 2010,107(9) :1071-1082.
  • 9Logue SE, Cleary P, Saveljeva S, et al. New directions in ER stress-induced cell death [ J ]. Apoptosis, 2013,18 ( 5 ) : 537- 546.
  • 10Hideshima T,Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma [ J ]. J Biol Chem, 2002,277 ( 19 ) : 16639-16647.

同被引文献22

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部